ATRA - Atara Biotherapeutics, Inc.
| Previous Close | 50.05 |
| Open | 50.30 |
| Bid | 46.05 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 50.26 - 54.45 |
| 52 Week Range | 11.80 - 54.45 |
| Volume | 1,183,444 |
| Avg. Volume | 692,509 |
| Market Cap | 2.261B |
| Beta | 3.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.16 |
| Earnings Date | Nov 2, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.60 |
- CNBC Videos•2 months ago
Cramer's lightning round: I screwed up on Apache and won'...
Jim Cramer zooms through his take on callers' favorite stocks, including a mea culpa on one oil play.
- GlobeNewswire•5 days ago
Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association
SOUTH SAN FRANCISCO, Calif., May 17, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune ...
- ACCESSWIRE•12 days ago
Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies
LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Atara Biotherapeutics, Inc. (NASDAQ: ATRA) ("Atara"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ATRA as the Company's latest news hit the wire. On May 08, 2018, the Company announced that it has expanded its collaboration with Memorial Sloan Kettering Cancer Center ("MSK") to develop the next generation of genetically engineered chimeric antigen receptor T-cell (CAR T) immunotherapies. Active-Investors.com is currently working on the research report for Cellectis S.A. (NASDAQ: CLLS), which also belongs to the Healthcare sector as the Company Atara Biotherapeutics.
- Associated Press•14 days ago
Atara Biotherapeutics: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of $1.05 per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•14 days ago
Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif., May 08, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune ...
- GlobeNewswire•14 days ago
Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Autoimmune and Other Diseases
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the Company has expanded its collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop the next generation of genetically engineered chimeric antigen receptor T-cell (CAR T) immunotherapies. This agreement is the next step in Atara’s strategy to leverage the potential of the Company’s technology platform to develop genetically modified off-the-shelf, allogeneic T-cell immunotherapies to transform the lives of patients with serious medical conditions. Under the agreement, Atara will gain access to several of MSK’s innovative enabling technologies, including a novel CAR T construct that Atara believes has physiologic T-cell activation properties, as well as methods for designing CAR T immunotherapies.
- GlobeNewswire•14 days ago
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 07, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune ...
- GlobeNewswire•15 days ago
Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development
SOUTH SAN FRANCISCO, Calif., May 07, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune ...
- GlobeNewswire•21 days ago
Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General Manager, Europe
SOUTH SAN FRANCISCO, Calif., May 01, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune ...
- Motley Fool•last month
3 Growth Stocks for Successful Investors
Investing success can sometimes be achieved by looking beyond the obvious choices. Check out the growth potential of Shopify, Atara Bio, and Criteo.
- GlobeNewswire•last month
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 09, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral ...
- GlobeNewswire•2 months ago
Recent Analysis Shows Multi-Color, Madrigal Pharmaceuticals, SPX, AngioDynamics, Atara Biotherapeutics, and Quanex Building Products Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
Atara Biotherapeutics to Participate in Three Upcoming Immuno-Oncology Conferences
SOUTH SAN FRANCISCO, Calif., March 22, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral ...
- GlobeNewswire•2 months ago
Atara Biotherapeutics to Present at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Post-transplant lymphoproliferative disorder following allogeneic hematopoietic cell transplant is an aggressive disease impacting a young population and carrying a significant mortality rate in a relatively ...
- CNBC•2 months ago
Cramer's lightning round: I screwed up on Apache and won't stop you from selling
Jim Cramer zooms through his take on callers' favorite stocks, including a mea culpa on one oil play.
- GlobeNewswire•2 months ago
Atara Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 06, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral ...
- GlobeNewswire•3 months ago
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral ...
- InvestorPlace•3 months ago
5 Biotech Stocks to Sell Amid the Latest Slaughter
Stocks are under fresh pressure after new Federal Reserve chairman Jerome Powell sounded a hawkish note in his first appearance before Congress this week. The odds of four quarter-point rate hikes is now rising fast, pressuring long-term Treasury yields higher, bringing back the headwind that pushed stocks into a correction earlier this month.
- GlobeNewswire•3 months ago
Atara Biotherapeutics Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral ...
- Associated Press•3 months ago
Atara Biotherapeutics reports 4Q loss
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.15. For the year, the company reported that its loss widened to $119.5 million, or $4 per share. Atara Biotherapeutics ...
- GlobeNewswire•3 months ago
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress
–Initiated two Phase 3 clinical studies to evaluate tab-cel™ in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder who have failed rituximab and opened six MATCH and ...
- Zacks•3 months ago
Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.
- GlobeNewswire•3 months ago
Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018
Launches Search for Chief Financial Officer. SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018-- Atara Biotherapeutics, Inc., a leading off-the-shelf T-cell immunotherapy company developing novel treatments for ...
- Market Realist•4 months ago
Behind Atara Biotherapeutics’ Recent Financial Performance
Atara Biotherapeutics Today: Gauging Investor Interest in ATRA
